Perilous Reversal Watch: Acorda Therapeutics (ACOR)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Acorda Therapeutics ( ACOR) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Acorda Therapeutics as such a stock due to the following factors:

ACOR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $49.8 million.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. ACOR has a PE ratio of 65.2. Currently there are 2 analysts that rate Acorda Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Acorda Therapeutics has been 443,900 shares per day over the past 30 days. Acorda has a market cap of $1.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.90 and a short float of 9.5% with 3.48 days to cover. Shares are up 28.8% year-to-date as of the close of trading on Wednesday.